Phase 3 Readouts
Phase 3 clinical trial readouts are pivotal moments for biotech companies. These large-scale trials (1,000-5,000+ patients) determine whether a drug has enough evidence of efficacy and safety to seek FDA approval.
200 phase 3 readouts tracked, next on Aug 31, 2026. Event dates and source records are shown with their available source context.
Phase 3 Topline: A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) an
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Phase 3 Topline: A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refra
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and To
NEUROCRINE BIOSCIENCES INC (NBIX)
Phase 3 Topline: Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult
ELI LILLY & Co (LLY)
Phase 3 Topline: Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthel
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Effica
Novartis AG (NVS)
Phase 3 Topline: A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Su
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension
AbbVie Inc. (ABBV)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active
AbbVie Inc. (ABBV)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Ev
West Pharmaceutical Services Inc. (WST)
Phase 3 Topline: ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Establ
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-3
Neumora Therapeutics, Inc. (NMRA)
Phase 3 Topline: A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azaci
AbbVie Inc. (ABBV)
Phase 3 Topline: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Aveluma
Royalty Pharma plc (RPRX)
Phase 3 Topline: A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Wi
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-3
Neumora Therapeutics, Inc. (NMRA)
Phase 3 Topline: A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety S
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
Phase 3 Topline: An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With
AbbVie Inc. (ABBV)
Phase 3 Topline: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Inves
ASTRAZENECA PLC (AZN)
Phase 3 Topline: An International, Multicenter, Open-label, Randomized, Comparative Study of the Efficacy and Safety
FATE THERAPEUTICS INC (FATE)
Phase 3 Topline: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulves
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects
BIOGEN INC. (BIIB)
Phase 3 Topline: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel
AMGEN INC (AMGN)
Phase 3 Topline: Open-Label Extension Study of Setmelanotide in Patients With a Rare Genetic, Syndromic or Acquired D
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Phase 3 Topline: A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Ef
AMGEN INC (AMGN)
Phase 3 Topline: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimil
Amphastar Pharmaceuticals, Inc. (AMPH)
Phase 3 Topline: An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or
KYNTRA BIO INC. (KYNB)
Phase 3 Topline: A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
PTC THERAPEUTICS, INC. (PTCT)
Phase 3 Topline: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of C
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of S
RHYTHM PHARMACEUTICALS, INC. (RYTM)
Phase 3 Topline: AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phas
Immutep Limited (IMMP)
Phase 3 Topline: A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Vers
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Randomized, Double-blind, Vehicle-controlled, Multicenter Phase III Study to Evaluate the Safety,
Biofrontera Inc. (BFRI)
Phase 3 Topline: SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN
PALVELLA THERAPEUTICS, INC. (PVLA)
Phase 3 Topline: A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Sa
Travere Therapeutics, Inc. (TVTX)
Phase 3 Topline: Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates?
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and
AMGEN INC (AMGN)
Phase 3 Topline: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Ope
ARGENX SE (ARGX)
Phase 3 Topline: Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. O
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Single-Arm, Open-Label, Safety Study in Patients With Generalized Lipodystrophy Switching From Met
REGENERON PHARMACEUTICALS, INC. (REGN)
Phase 3 Topline: A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to So
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VARIANT
BioNTech SE (BNTX)
Phase 3 Topline: A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-2
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Phase 3 Topline: Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic R
Nasus Pharma Ltd (NSRX)
Phase 3 Topline: An International, Multicenter, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluat
AbbVie Inc. (ABBV)
Phase 3 Topline: A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to De
Novartis AG (NVS)
Phase 3 Topline: A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing t
AbbVie Inc. (ABBV)
Phase 3 Topline: A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy
GH Research PLC (GHRS)
Phase 3 Topline: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein
Novartis AG (NVS)
Phase 3 Topline: A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BNT162B2 (LP.8.1
BioNTech SE (BNTX)
Phase 3 Topline: A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Re
Moderna, Inc. (MRNA)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ef
ELI LILLY & Co (LLY)
Phase 3 Topline: A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants Wit
BIOGEN INC. (BIIB)
Phase 3 Topline: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb/III Study to Assess the Effica
TG THERAPEUTICS, INC. (TGTX)
Phase 3 Topline: A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndr
Quoin Pharmaceuticals, Ltd. (QNRX)
Phase 3 Topline: A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY EVALUATING THE SAFETY, TOLERA
BioNTech SE (BNTX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy
BIOMARIN PHARMACEUTICAL INC (BMRN)
Phase 3 Topline: A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy
Arcus Biosciences, Inc. (RCUS)
Phase 3 Topline: Donepezil Use Versus Non-drug Approach in Treatment of Newly Diagnosed Alzheimer's Disease : a Multi
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
Pharvaris N.V. (PHVS)
Phase 3 Topline: A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult P
West Pharmaceutical Services Inc. (WST)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Serum Virus Neutralizing Antibody
Invivyd, Inc. (IVVD)
Phase 3 Topline: A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of
Invivyd, Inc. (IVVD)
Phase 3 Topline: A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vada
Akebia Therapeutics, Inc. (AKBA)
Phase 3 Topline: A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Te
AbbVie Inc. (ABBV)
Phase 3 Topline: A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Par
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Sa
IONIS PHARMACEUTICALS INC (IONS)
Phase 3 Topline: A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) i
AMGEN INC (AMGN)
Phase 3 Topline: A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezoliz
Jazz Pharmaceuticals plc (JAZZ)
Phase 3 Topline: A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety
Zenas BioPharma, Inc. (ZBIO)
Phase 3 Topline: Comparison of Efficacy of Tranexamic Acid Versus Vasopressin in Blood Loss Among Placenta Previa Pat
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoe
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain
Alkermes plc. (ALKS)
Phase 3 Topline: A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in
Vanda Pharmaceuticals Inc. (VNDA)
Phase 3 Topline: Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatmen
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Phase 3 Topline: A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Co
CYBIN INC. (HELP)
Phase 3 Topline: Opiate-sparing Post-operative Pain Control in Septorhinoplasty: A Prospective Randomized, Double Bli
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Effi
ARDELYX, INC. (ARDX)
Phase 3 Topline: Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Phase 3 Topline: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel For
UroGen Pharma Ltd. (URGN)
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Eff
Veradermics Incorporated (MANE)
Phase 3 Topline: A Phase 3, Multicenter, Open-label, Single-arm Study to Assess the Efficacy and Safety of Apremilast
AMGEN INC (AMGN)
Phase 3 Topline: PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Cha
Novartis AG (NVS)
Phase 3 Topline: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemothera
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monot
PFIZER INC (PFE)
Phase 3 Topline: A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone
Teva Pharmaceutical Industries Limited (TEVA)
Phase 3 Topline: A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 V
Novartis AG (NVS)
Phase 3 Topline: A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combinati
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PI
Ocugen, Inc. (OCGN)
Phase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Soneloki
MoonLake Immunotherapeutics (MLTX)
Phase 3 Topline: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Ac
ARGENX SE (ARGX)
Phase 3 Topline: A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Afica
CYTOKINETICS INC (CYTK)
Phase 3 Topline: Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharm
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner i
Xenon Pharmaceuticals Inc. (XENE)
Phase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W
Viridian Therapeutics, Inc.\DE (VRDN)
Phase 3 Topline: A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Effi
Biohaven Ltd. (BHVN)
Phase 3 Topline: A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Pa
Sol-Gel Technologies Ltd. (SLGL)
Phase 3 Topline: A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Organon & Co. (OGN)
Phase 3 Topline: US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol
Vistagen Therapeutics, Inc. (VTGN)
Phase 3 Topline: Diagnostic Testing of Post-Traumatic Stress Disorder (PTSD) Using the Senseye Diagnostic Tool in Adu
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy,
Disc Medicine, Inc. (IRON)
Phase 3 Topline: A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Saf
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥
REGENERON PHARMACEUTICALS, INC. (REGN)
Phase 3 Topline: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermed
GERON CORP (GERN)
Phase 3 Topline: A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compa
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates
Filana Therapeutics Inc. (FLNA)
Phase 3 Topline: Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutan
Novo Nordisk A/S (NVO)
Phase 3 Topline: CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controll
Cardiol Therapeutics Inc. (CRDL)
Phase 3 Topline: A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozel
REGENERON PHARMACEUTICALS, INC. (REGN)
Phase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase IIIb Study Evalua
Novartis AG (NVS)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua
NYMOX PHARMACEUTICAL CORP (NYMXF)
Phase 3 Topline: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combina
VERTEX PHARMACEUTICALS INC / MA (VRTX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evalua
GH Research PLC (GHRS)
Phase 3 Topline: A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line T
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Phase 3 Topline: A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Dos
Sarepta Therapeutics, Inc. (SRPT)
Phase 3 Topline: A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Eff
Teva Pharmaceutical Industries Limited (TEVA)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLua
Dianthus Therapeutics, Inc. /DE/ (DNTH)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit
IO Biotech, Inc. (IOBTQ)
Phase 3 Topline: Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to
AbbVie Inc. (ABBV)
Phase 3 Topline: An Open-Label, Single-Arm, Historically Controlled, Prospective, Multi-Center Phase III Study to Eva
Canopy Growth Corp (CGC)
Phase 3 Topline: Study of Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
MEDICURE INC (MCUJF)
Phase 3 Topline: A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Ret
ELI LILLY & Co (LLY)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safet
Ensysce Biosciences Inc. (ENSC)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a
Definium Therapeutics Inc. (DFTX)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy a
ASTRAZENECA PLC (AZN)
Phase 3 Topline: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prosta
CG Oncology, Inc. (CGON)
Phase 3 Topline: A Phase 3, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Trial to Evalu
AMGEN INC (AMGN)
Phase 3 Topline: REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil
Viridian Therapeutics, Inc.\DE (VRDN)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effica
AMGEN INC (AMGN)
Phase 3 Topline: A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Plat
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses
Novartis AG (NVS)
Phase 3 Topline: Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Design Therapeutics, Inc. (DSGN)
Phase 3 Topline: A Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo Af
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placeb
ELI LILLY & Co (LLY)
Phase 3 Topline: Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial
GH Research PLC (GHRS)
Phase 3 Topline: A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of the
GH Research PLC (GHRS)
Phase 3 Topline: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monoth
SELLAS Life Sciences Group, Inc. (SLS)
Phase 3 Topline: A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel
Compass Therapeutics, Inc. (CMPX)
Phase 3 Topline: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficac
Biohaven Ltd. (BHVN)
Phase 3 Topline: ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metasta
KYNTRA BIO INC. (KYNB)
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge E
Axsome Therapeutics, Inc. (AXSM)
Phase 3 Topline: A Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis
West Pharmaceutical Services Inc. (WST)
Phase 3 Topline: A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety
Axsome Therapeutics, Inc. (AXSM)
Phase 3 Topline: RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing
Immunome Inc. (IMNM)
Phase 3 Topline: The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of T
Vanda Pharmaceuticals Inc. (VNDA)
Phase 3 Topline: Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety a
DiaMedica Therapeutics Inc. (DMAC)
Phase 3 Topline: A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, To
Xenon Pharmaceuticals Inc. (XENE)
Phase 3 Topline: Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Plac
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy an
AbbVie Inc. (ABBV)
Phase 3 Topline: The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Af
ANI PHARMACEUTICALS INC (ANIP)
Phase 3 Topline: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) Wi
Karyopharm Therapeutics Inc. (KPTI)
Phase 3 Topline: Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvi
Atea Pharmaceuticals, Inc. (AVIR)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compare
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Predniso
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepa
UNITED THERAPEUTICS Corp (UTHR)
Phase 3 Topline: A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Ab
Krystal Biotech, Inc. (KRYS)
Phase 3 Topline: A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Sa
COMPASS Pathways plc (CMPS)
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pha
ELI LILLY & Co (LLY)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluatin
ELI LILLY & Co (LLY)
Phase 3 Topline: An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inh
Gossamer Bio, Inc. (GOSS)
Phase 3 Topline: HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Phase 3 Topline: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Ex
Valneva SE (VALN)
Phase 3 Topline: Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and A
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Eff
GH Research PLC (GHRS)
Phase 3 Topline: ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute M
Novo Nordisk A/S (NVO)
Phase 3 Topline: A Randomized, Double-blind Study to Compare the Pharmacokinetics Between ABP 234 and Keytruda® (Pemb
AMGEN INC (AMGN)
Phase 3 Topline: REVEAL-2 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerabil
Viridian Therapeutics, Inc.\DE (VRDN)
Phase 3 Topline: Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenf
IDEAYA Biosciences, Inc. (IDYA)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Saf
Valneva SE (VALN)
Phase 3 Topline: A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the E
GH Research PLC (GHRS)
Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Trial of Dalargin for the Prevention of Postoperative
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety
BRISTOL MYERS SQUIBB CO (BMY)
Phase 3 Topline: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combina
ASTRAZENECA PLC (AZN)
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of
BIO-TECHNE Corp (TECH)
Phase 3 Topline: A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Parti
Incyte Corp. (INCY)
Phase 3 Topline: Early Commencement of Adjuvant Chemotherapy for Stage III Colon Cancer: a Multicenter Randomized Tri
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study to Evaluate
GH Research PLC (GHRS)
Phase 3 Topline: A Phase II/III Study of SPH4336 in Combination With Endocrine Therapy in the Treatment of HR-positiv
X4 Pharmaceuticals, Inc (XFOR)
Phase 3 Topline: A Randomized, Open, Multicenter Phase III Clinical Trial of Combination of Sintilimab Injection (IBI
ENANTA PHARMACEUTICALS INC (ENTA)
Phase 3 Topline: A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF VEPDEGESTRANT (ARV-471/PF-07850327) PLUS PAL
PFIZER INC (PFE)
Phase 3 Topline: An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of L
Q/C TECHNOLOGIES, INC. (QCLS)
Phase 3 Topline: An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Com
Novartis AG (NVS)
Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Effic
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH)
Phase 3 Topline: A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and S
GH Research PLC (GHRS)
Phase 3 Topline: A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrex
Summit Therapeutics Inc. (SMMT)
Phase 3 Topline: An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term
INSMED Inc (INSM)
Phase 3 Topline: Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Wit
Relay Therapeutics, Inc. (RLAY)
Phase 3 Topline: Randomized Prospective Study Comparing Intrathecal Morphine vs Intravenous Methadone for Postoperati
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Effi
Crinetics Pharmaceuticals, Inc. (CRNX)
Phase 3 Topline: A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered As a Single Agent or
ENANTA PHARMACEUTICALS INC (ENTA)
Frequently asked questions
What is a Phase 3 topline readout?
It is the first public release of primary-endpoint results from a pivotal Phase 3 trial, determining whether a drug has enough evidence to seek FDA approval.
Why are Phase 3 readouts high-risk catalysts?
Phase 3 trials are large and expensive; missing the primary endpoint can erase most of a clinical-stage company's value, while a hit de-risks the path to approval.
How are Phase 3 readout dates sourced?
Expected readout windows are derived from ClinicalTrials.gov completion dates and company guidance; source context is shown where available.
Learn more
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Biotech Competitive Landscape Analysis: How to Map Drug Pipelines and Identify Winners
Learn how to analyze the competitive landscape in biotech, compare drug pipelines across companies, evaluate first-mover advantage, and identify best-in-class opportunities.
Key terms
From catalyst type to protocol condition
Decide when this event type should matter
Set the timing, confidence, company, drug, trial, and financing conditions that must hold before this catalyst changes a decision.